Zacks Research Comments on Amarin Co. plc's Q2 2025 Earnings (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Amarin in a research note issued on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their previous forecast of ($0.05). The consensus estimate for Amarin's current full-year earnings is ($0.14) per share. Zacks Research also issued estimates for Amarin's Q1 2026 earnings at ($0.05) EPS.

Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. Amarin had a negative return on equity of 9.43% and a negative net margin of 18.96%. The business had revenue of $56.52 million during the quarter, compared to analysts' expectations of $51.34 million. During the same period in the prior year, the business posted ($0.04) EPS.

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Amarin in a research note on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $1.08.

Amarin Price Performance

Shares of Amarin stock traded down $0.01 during trading on Friday, hitting $0.91. 462,986 shares of the stock were exchanged, compared to its average volume of 1,923,743. The stock has a market cap of $373.71 million, a price-to-earnings ratio of -7.57 and a beta of 1.96. The firm's 50-day moving average price is $0.95 and its 200 day moving average price is $0.94. Amarin has a 12-month low of $0.65 and a 12-month high of $1.49.

Hedge Funds Weigh In On Amarin

Hedge funds have recently modified their holdings of the business. Newbridge Financial Services Group Inc. purchased a new position in shares of Amarin during the first quarter worth about $37,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 34,725 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in Amarin by 100.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 23,313 shares in the last quarter. SVB Wealth LLC raised its position in Amarin by 100.0% in the fourth quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company's stock worth $52,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Gilliland Jeter Wealth Management LLC bought a new position in shares of Amarin during the 4th quarter valued at about $64,000. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.